Iboga Treatment

    What is an Iboga Treatment?

    An Iboga Treatment works with what is known as the godfather of all plant medicines, Iboga. Iboga is the inner root bark of a rainforest shrub called Tabernanthe Iboga. It has been used by West African tribes for thousands of years for its medicinal and spiritual properties as a part of the spiritual tradition Bwiti. The roots of the herb contain several bioactive alkaloids, with the most well-known being Ibogaine. 

    Iboga Treatment is another way of saying Iboga Ceremony, Iboga Therapy, or Iboga Retreat. All of these terms usually mean the same thing. Iboga can help with many mental, physical, and spiritual conditions, which is why we offer several different types of Iboga Treatments at Root Healing

    Our Iboga Treatments

    Bwiti Psychospiritual Retreats

    Our Bwiti ceremonies create a safe and sacred space to journey within and connect with your deepest truths. With the support of our experienced team, you will have the opportunity to release old traumas and wounds, connect with your intuition and inner wisdom, and rediscover your authentic self.

    Learn More

    Iboga Detox Treatment

    Our Iboga Detox Treatment offers a permanent holistic solution to those suffering from various types of addiction. This includes a full detox treatment and additional ceremonies. By combining ancient Bwiti techniques with modern science, this program ensures a safe and effective healing process. 

    Learn More

    Specialized Iboga Treatments

    Our Specialized Iboga Treatments are beneficial solutions for people suffering from certain physical, mental, and spiritual conditions that require personalized care. Individual treatment plans are created for treating conditions like Parkinson’s, Autoimmune conditions, Traumatic Brain Injuries, and more.

    Learn More

    What is an Ibogaine Treatment?

    Ibogaine treatments work with Ibogaine and tend to have a very clinical approach, often performed in a hospital type of setting. There is little to no spiritual healing, counseling, or integration coaching like you would receive with an Iboga Treatment. We do not offer Ibogaine Treatments at Root Healing, but we may sometimes use Ibogaine as part of the program in unique cases.

    Iboga or Ibogaine Treatment? What's better?

    While both therapies have high success rates, Iboga Treatments done in the traditional way are more effective for many scientific and spiritual reasons. Our combination of both the Bwiti tradition and modern medical science is more effective for lasting healing.

    Here are some of the reasons why:

    Beneficial Alkaloids

    In Ibogaine Treatment centers, only the alkaloid Ibogaine is used, which misses out on the full potential of the complete plant.

    In fact, the root bark contains many beneficial alkaloids. Apart from Ibogaine, other prominent molecules include tabernanthine (13-methoxy ibogamine), ibogamine, coronaridine, ibogaline, and others.

    Scientists have investigated the effectiveness of these alkaloids in attenuating drug-seeking behavior in animals, and they have found that tabernanthine, ibogamine, and coronaridine possess potent anti-addictive properties similar to Ibogaine (2).

    This means that the benefits of Ibogaine will be potentiated when used in conjunction with the rest of the alkaloids. Thus, we recommend an Iboga Treatment as a more effective option for attenuating drug craving and withdrawal symptoms.

    Iboga may be more beneficial than Ibogaine for other conditions as well, such as alleviating symptoms of depression. Both Ibogaine and tabernanthine activate receptors in the brain called sigma-2 (3). According to the research, activating these receptors can have several benefits for brain function, including antidepressant effects.

    The root bark contains many beneficial alkaloids. Apart from Ibogaine, other prominent molecules include tabernanthine (13-methoxy ibogamine), ibogamine, coronaridine, ibogaline, and others. Scientists have investigated the effectiveness of these alkaloids in attenuating drug-seeking behavior in animals, and they have found that tabernanthine, ibogamine, and coronaridine possess potent anti-addictive properties similar to Ibogaine

    Pub Med

    Spiritual Tradition

    Ibogaine Treatments also lack the spiritual tradition that is crucial to healing with Iboga. The Bwiti have worked with Iboga for thousands of years. Iboga is the Bwiti’s sacrament, and its spirit has communicated to them directly about how to work with it. The rituals and traditions of a Bwiti-focused Iboga treatment were given to the Bwiti by the spirit of Iboga itself, enhancing its strength, efficacy, and healing results.

    Moreover, when Ibogaine has been fully extracted from the Iboga, it no longer has the spirit of the medicine. Thus, the treatment will only provide temporary mental and physical healing. 

    All the Iboga we use at our Iboga Treatments comes directly from our Bwiti family and is handled with traditional care to ensure that the spirit remains strong. In addition, our Total Alkaloid (TA) extract is also made with a unique spiritual process that ensures the spirit stays.

    learn more

    Iboga and Ibogaine Treatments for Addiction

    Ibogaine has been extensively studied when it comes to treating symptoms of addiction and withdrawal from opioids and opiates (natural opioids). As mentioned above, some of the other alkaloids in Iboga, like tabernanthine, ibogamine, and coronaridine, also possess potent anti-addictive properties similar to Ibogaine (1) (2). (4)(5) (6)

    A single dose of Ibogaine appears effective in treating cocaine addiction as well. Other published scientific observations also confirm the benefits of Ibogaine on cocaine addiction and withdrawal (7). (8). 

    Another report of 75 previous alcohol, cannabis, cocaine, and crack users reveals that a single Ibogaine treatment led to several months of abstinence in 61% of the patients, while additional treatments prolonged the suppressing effects on drug-seeking behavior (9).

    In addition, by increasing the activity of NGF and BDNF, Ibogaine may be able to rejuvenate some of the damage that occurs to these factors after years of opioid and cocaine abuse (24, 25).

    What sets our Iboga Detox Treatment apart is our extended program. Along with initial detox treatment, we include several psychospiritual ceremonies and counseling to heal the underlying causes of the addiction and promote new patterns of living. In addition, our extensive aftercare program ensures they stay on track and have the support they need for lasting success. 

    learn more

    Iboga and Ibogaine Treatments for Mental Health

    Depression and anxiety disorders are relatively common among drug addicts because addiction often occurs in an attempt to cope with psychological symptoms. With that being said, most studies investigating the benefits of Ibogaine for addiction and withdrawal also report significant improvement in symptoms of depression after the treatment (5, 7, 10). In fact, Ibogaine was initially marketed in France in the 1930s as a product for depression and fatigue (11). 

    Increasing serotonin levels is one of the main targets of pharmacological therapy with antidepressants. Furthermore, increasing dopamine may also improve symptoms of depression. If dopamine levels are insufficient, it may lead to mood problems, including depressed mood, lack of motivation, and feelings of hopelessness. Ibogaine increases the bioavailability of these molecules in the brain. (12, 13). 

    Ibogaine also appears effective in certain forms of anxiety, such as PTSD (post-traumatic stress disorder). According to a study of 51 US veterans, a single oral dose (10 mg/kg) of Ibogaine significantly reduced symptoms of depression, anxiety, and PTSD (16). The treatment also led to major reductions in suicidal tendencies and cognitive impairment.

    While the science shows some truly remarkable results, the true benefits of an Iboga Treatment are in the experience. Guests at a retreat are able to see the root causes of their depression, anxiety, or other mental health problems. The treatment also helps them detox their mind and sets them free. Most importantly, though, it connects them to their true selves. Going home with a clean slate, a restored brain, and the neuroplasticity to build new healthier habits is a recipe for success.

    Benefits of Iboga and Ibogaine for Neuroplasticity

    Neuroplasticity is the potential of the brain to learn, adapt and recover. It’s the result of the brain cells’ ability to form new connections and reorganize. The growth factors in the brain that stimulate this process and ensure the survival of nerve cells are called neurotrophic factors. According to research, Ibogaine may increase the activity of several neurotrophic factors in the brain, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell-derived neurotrophic factor (GDNF) (21). (22).

    In fact, the benefits of Ibogaine on GDNF persist even after the alkaloid has left your system (23). (24, 25). BDNF is also shown to help nerve cells create new connections, survive, repair, and even form anew in areas of the brain that retain stem cells (26, 27).

    Ibogaine and Iboga Treatment Benefits for Physical Conditions

    Traumatic Brain Injury

    The effects of Iboga and its alkaloids, such as Ibogaine, on various receptors and neurotrophic factors in the brain, may hide a potential for treating certain neurological conditions.

    For example, restoring the activity of BDNF in the brain may boost the recovery of patients with traumatic brain injury (TBI) (28).

    TBI is a term describing damage to the brain (such as a concussion) that has occurred due to external force. Severe or repeated injuries can lead to irreparable brain damage and disabilities.

    Since Ibogaine stimulates the activity of BDNF in certain areas of the brain, the alkaloid may be able to induce neural regeneration, reconnection, dendritic sprouting, and improved synaptic efficacy. 

    This, in turn, may reverse cognitive and emotional deficits in TBI patients. In addition, animal studies support the effectiveness of BDNF activation, which was able to cause a complete brain repair after a TBI (29).

    MRI

    Parkinson's

    Parkinson’s disease may also be ameliorated by Iboga and Ibogaine’s effects on neuroplasticity. The condition is caused by the death of dopaminergic neurons.

    GDNF has been extensively investigated as a possible agent that can prevent the death of brain cells and restore function in the dopaminergic brain cells that are affected by the condition (30).

    Studies have shown up to 40% improvement in symptoms after direct GDNF infusion. However, the procedure is invasive, complicated, and inconvenient.

    On the other hand, Ibogaine has been proven to upregulate GDNF expression in the same regions which are otherwise affected in Parkinson’s and thus may prove to be an effective and less invasive treatment option (21).

    Furthermore, the activation of the sigma-1 receptor by Ibogaine and other alkaloids in Iboga may also provide benefits against neurological diseases (31). For example, the activation of the receptor may help patients with Parkinson’s by reducing neuroinflammation (32).

    Autoimmune and Multiple Sclerosis

    Studies have also shown that reducing inflammation in the brain is especially effective in autoimmune neurological conditions such as multiple sclerosis (MS) and autoimmune encephalomyelitis (inflammation of the brain and the spinal cord).

    In one experimental animal model of autoimmune encephalomyelitis, sigma-1 activation prevented the accumulation of immune cells and degeneration of neurons which slowed down the progression of the condition (33).

    Bacteria, Viruses, and Fungal Pathogens

    Ibogaine may also possess antimicrobial properties, including antiretroviral, antimycobacterial, and antimycotic effects. One in vitro study has reported that Ibogaine has activity against the bacteria that causes tuberculosis – Mycobacterium tuberculosis (17). 

    Ibogaine can also block the replication of the Human Immunodeficiency Virus (HIV) that causes AIDS and may stop the spreading of the virus (18). Ibogaine is highly effective against one of the most common fungal pathogens – Candida albicans. (19). (20).

    In one experimental animal model of autoimmune encephalomyelitis, sigma-1 activation prevented the accumulation of immune cells and degeneration of neurons which slowed down the progression of the condition (33).

    Conclusion

    Treatment with Ibogaine has shown great success in attenuating symptoms of addiction and withdrawal, as well as great promise in the therapy of depression, PTSD, and other health conditions.

    Despite the fact that Ibogaine therapy has been extensively studied, an Iboga Treatment using the isolated alkaloid extract or root bark is far more effective and efficient than Ibogaine therapy. Traditional Bwiti Iboga treatments not only heal physically but also mentally and spiritually.

    Root Healing Iboga Treatments combine the best of both worlds with a medical and Bwiti-trained team offering comprehensive, holistic treatments.

    References:

    1. Lotsof, H. S., & Alexander, N. E. (2001). Case studies of ibogaine treatment: implications for patient management strategies. The Alkaloids. Chemistry and biology, 56, 293–313. https://doi.org/10.1016/s0099-9598(01)56020-4 
    2. Glick, S. D., Kuehne, M. E., Raucci, J., Wilson, T. E., Larson, D., Keller, R. W., Jr, & Carlson, J. N. (1994). Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain research, 657(1-2), 14–22. https://doi.org/10.1016/0006-8993(94)90948-2 
    3. Popik, P., & Skolnick, P. (1999). Pharmacology of Ibogaine and Ibogaine-Related Alkaloids. Alkaloids: Chemistry and Biology, 52(C), 197–231. https://doi.org/10.1016/S0099-9598(08)60027-9 
    4. Alper, K. R., Lotsof, H. S., Frenken, G. M., Luciano, D. J., & Bastiaans, J. (1999). Treatment of acute opioid withdrawal with ibogaine. The American journal on addictions, 8(3), 234–242. https://doi.org/10.1080/105504999305848 
    5. Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American journal of drug and alcohol abuse, 44(1), 37–46. https://doi.org/10.1080/00952990.2017.1310218 
    6. Davis, A. K., Barsuglia, J. P., Windham-Herman, A. M., Lynch, M., & Polanco, M. (2017). Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning. Journal of psychedelic studies, 1(2), 65–73. https://doi.org/10.1556/2054.01.2017.009 
    7. Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., Singleton, E. G., & Mayor, M. (2000). Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences, 914, 394–401. https://doi.org/10.1111/j.1749-6632.2000.tb05213.x 
    8. Luciano D. (1998). Observations on treatment with ibogaine. The American journal on addictions, 7(1), 89–90. https://doi.org/10.1111/j.1521-0391.1998.tb00472.x 
    9. Schenberg, E. E., de Castro Comis, M. A., Chaves, B. R., & da Silveira, D. X. (2014). Treating drug dependence with the aid of ibogaine: a retrospective study. Journal of psychopharmacology (Oxford, England), 28(11), 993–1000. https://doi.org/10.1177/0269881114552713 
    10. Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R., Ervin, F. R., Kamlet, J. D., & Hearn, W. L. (2001). Ibogaine in the treatment of heroin withdrawal. The Alkaloids. Chemistry and biology, 56, 155–171. https://doi.org/10.1016/s0099-9598(01)56012-5 
    11. Goutarel, R., Gollnhofer, O., & Sillans, R. (1993). Pharmacodynamics and therapeutic applications of iboga and ibogaine. Psychedelic Monographs and Essays, 6, 70-111.
    12. Bulling, S., Schicker, K., Zhang, Y. W., Steinkellner, T., Stockner, T., Gruber, C. W., Boehm, S., Freissmuth, M., Rudnick, G., Sitte, H. H., & Sandtner, W. (2012). The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. The Journal of biological chemistry, 287(22), 18524–18534. https://doi.org/10.1074/jbc.M112.343681 
    13. Wells, G. B., Lopez, M. C., & Tanaka, J. C. (1999). The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes. Brain research bulletin, 48(6), 641–647. https://doi.org/10.1016/s0361-9230(99)00053-2 
    14. Belujon, P., & Grace, A. A. (2017). Dopamine System Dysregulation in Major Depressive Disorders. The international journal of neuropsychopharmacology, 20(12), 1036–1046. https://doi.org/10.1093/ijnp/pyx056 
    15. Forsyth, B., Machado, L., Jowett, T., Jakobi, H., Garbe, K., Winter, H., & Glue, P. (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of ethnopharmacology, 189, 10–13. https://doi.org/10.1016/j.jep.2016.05.022 
    16. Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020). Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic stress (Thousand Oaks, Calif.), 4, 2470547020939564. https://doi.org/10.1177/2470547020939564 
    17. Rastogi, N., Abaul, J., Goh, K. S., Devallois, A., Philogène, E., & Bourgeois, P. (1998). Antimycobacterial activity of chemically defined natural substances from the Caribbean flora in Guadeloupe. FEMS immunology and medical microbiology, 20(4), 267–273. https://doi.org/10.1111/j.1574-695X.1998.tb01136.x 
    18. Silva, E. M., Cirne-Santos, C. C., Frugulhetti, I. C., Galvão-Castro, B., Saraiva, E. M., Kuehne, M. E., & Bou-Habib, D. C. (2004). Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta medica, 70(9), 808–812. https://doi.org/10.1055/s-2004-827227 
    19. Yordanov, M., Dimitrova, P., Patkar, S., Saso, L., & Ivanovska, N. (2008). Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection. Canadian journal of microbiology, 54(6), 435–440. https://doi.org/10.1139/w08-029 
    20. Yordanov, M., Dimitrova, P., Patkar, S., Falcocchio, S., Xoxi, E., Saso, L., & Ivanovska, N. (2005). Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections. Journal of medical microbiology, 54(Pt 7), 647–653. https://doi.org/10.1099/jmm.0.45919-0 
    21. Marton, S., González, B., Rodríguez-Bottero, S., Miquel, E., Martínez-Palma, L., Pazos, M., Prieto, J. P., Rodríguez, P., Sames, D., Seoane, G., Scorza, C., Cassina, P., & Carrera, I. (2019). Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in pharmacology, 10, 193. https://doi.org/10.3389/fphar.2019.00193 
    22. Corne, R., & Mongeau, R. (2019). Utilisation des psychédéliques en psychiatrie : lien avec les neurotrophines [Neurotrophic mechanisms of psychedelic therapy]. Biologie aujourd’hui, 213(3-4), 121–129. https://doi.org/10.1051/jbio/2019015 
    23. He, D. Y., & Ron, D. (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 20(13), 2420–2422. https://doi.org/10.1096/fj.06-6394fje 
    24. Angelucci, F., Ricci, V., Pomponi, M., Conte, G., Mathé, A. A., Attilio Tonali, P., & Bria, P. (2007). Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. Journal of psychopharmacology (Oxford, England), 21(8), 820–825. https://doi.org/10.1177/0269881107078491 
    25. Pitts, E. G., Li, D. C., & Gourley, S. L. (2018). Bidirectional coordination of actions and habits by TrkB in mice. Scientific reports, 8(1), 4495. https://doi.org/10.1038/s41598-018-22560-x 
    26. Lu,, B. & Figurov,, A. (1997). Role of Neurotrophins in Synapse Development and Plasticity: . Reviews in the Neurosciences, 8(1), 1-12. https://doi.org/10.1515/REVNEURO.1997.8.1.1
    27. Zigova, T., Pencea, V., Wiegand, S. J., & Luskin, M. B. (1998). Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Molecular and cellular neurosciences, 11(4), 234–245. https://doi.org/10.1006/mcne.1998.0684 
    28. Kaplan, G. B., Vasterling, J. J., & Vedak, P. C. (2010). Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behavioural pharmacology, 21(5-6), 427–437. https://doi.org/10.1097/FBP.0b013e32833d8bc9 
    29. Cacialli, P., Palladino, A., & Lucini, C. (2018). Role of brain-derived neurotrophic factor during the regenerative response after traumatic brain injury in adult zebrafish. Neural regeneration research, 13(6), 941–944. https://doi.org/10.4103/1673-5374.233430 
    30. Gill, S. S., Patel, N. K., Hotton, G. R., O’Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature medicine, 9(5), 589–595. https://doi.org/10.1038/nm850 
    31. Thompson, C., & Szabo, A. (2020). Psychedelics as a novel approach to treating autoimmune conditions. Immunology letters, 228, 45–54. https://doi.org/10.1016/j.imlet.2020.10.001 
    32. Jia, J., Cheng, J., Wang, C., & Zhen, X. (2018). Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Frontiers in cellular neuroscience, 12, 314. https://doi.org/10.3389/fncel.2018.00314 
    33. Oxombre, B., Lee-Chang, C., Duhamel, A., Toussaint, M., Giroux, M., Donnier-Maréchal, M., Carato, P., Lefranc, D., Zéphir, H., Prin, L., Melnyk, P., & Vermersch, P. (2015). High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. British journal of pharmacology, 172(7), 1769–1782. https://doi.org/10.1111/bph.13037